Abstract: A device to deliver drugs via transmucosal absorption in the oral cavity and methods of administering same. The device of the present invention includes a drug-releasing element, where the drug-releasing element includes at least one drug and where the drug-releasing element is capable of delivering at least one drug to the oral cavity, and an external securing element.

Abstract: A substituted phenol compound represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof. At least one of X and Y is CH, and the other one of X and Y is N or CH. R1 is C1-C4 alkyl or C1-C4 haloalkyl. R2 is C1-C4 alkyl, or halogen. R3 is H, C1-C4 alkyl, aryl, or —(CH2)n-aryl, in which n is 1, 2, or 3. The compound is useful as anticonvulsant.

Abstract: Disclosed are compounds, compositions and methods for stopping seizures, including status epilepticus, and are useful for the treatment and prevention of seizure disorders.

Abstract: Substituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: Substituted hydrofluoroalkylphenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: The present invention relates to the synthesis of fluorinated forms of alkyl phenol compounds and their subsequent use as pharmaceutical agents. More specifically, alkyl phenol compounds are fluorinated to increase compound volatility such that the compound may be administered to a mammal, such as a human being, by inhalation. The invention also provides an inhaler (or vaporizer), that can be used for administration of the volatile derivatives of fluorine-substituted alkyl phenol compound. Further, different derivatives of fluorine-substituted alkyl phenol compound can be also administered by other routes as described in this document.

Abstract: Disclosed are compounds that can serve as melatonin analogue prodrugs and that are soluble in aqueous solvents. Melatonin or melatonin analogues having modifications to the indole moiety are coupled to a tertiary amine to form a quaternary amine such that there is a saturated two-carbon linkage between the carbonyl of the melatonin structure and the amine nitrogen. This structure is stable in acidic environments, but is unstable at basic or neutral pH. Therefore, these melatonin analogue prodrugs are stable in a vial at acidic pH, but will breakdown upon injection into the body to liberate the melatonin analogue and the tertiary amine, which is nontoxic. The melatonin analogue being not modified on the indole moiety exerts similar pharmacological properties as melatonin: antioxidation, sedation and anesthesia.

Abstract: Substituted hydrofluoroalkylphenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.

Abstract: The present invention relates to the synthesis of fluorinated forms of alkyl phenol compounds and their subsequent use as pharmaceutical agents. More specifically, alkyl phenol compounds are fluorinated to increase compound volatility such that the compound may be administered to a mammal, such as a human being, by inhalation. The invention also provides an inhaler (or vaporizer), that can be used for administration of the volatile derivatives of fluorine-substituted alkyl phenol compound. Further, different derivatives of fluorine-substituted alkyl phenol compound can be also administered by other routes as described in this document.

Abstract: Melatonin (N-acetyl-5-methoxytryptamine), or its biologically active analogues, are used to induce anesthesia.

Abstract: The present invention relates to the synthesis of fluorinated forms of alkyl phenol compounds and their subsequent use as pharmaceutical agents. More specifically, alkyl phenol compounds are fluorinated to increase compound volatility such that the compound may be administered to a mammal, such as a human being, by inhalation. The invention also provides an inhaler (or vaporizer), that can be used for administration of the volatile derivatives of fluorine-substituted alkyl phenol compound. Further, different derivatives of fluorine-substituted alkyl phenol compound can be also administered by other routes as described in this document.

Abstract: Melatonin (N-acetyl-5-methoxytryptamine), or its biologically active analogues, are used to induce anesthesia.

Abstract: Use of D2-sevoflurane is disclosed as an inhalational anesthetic. Deuterated sevoflurane possess all of the desirable qualities of sevoflurane as an anesthetic and is metabolized more slowly thereby reducing potentially toxic inorganic fluoride release. More particularly, the compound fluorodideutero methyl 1,1,1,3,3,3-hexafluoropropyl ether is disclosed as well as a method for synthesis.

Abstract: The invention relates to a method of synthesizing 1,1,1,3,3,3-hexafluoropropanes comprsing the additon of BrF.sub.3 to malononitrile.

Abstract: This invention relates to a method of synthesizing 1,1,1,3,3,3-hexafluoroisopropyl ether compounds from the reaction of methoxymalanonitrile with a bromine trifluoride composition.

Abstract: In the process of using sevoflurane as a rapid anesthetic, breakdown of the anesthetic to harmful compound A is slowed if not stopped altogether by cooling the CO.sub.2 scrubber to temperatures that still allow it to work effectively as scrubber but avoid sevoflurane degradation.